Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
BACKGROUND AND OBJECTIVES
Hypertherm intraperitoneal chemotherapy (HIPEC) is increasingly used in the treatment of ovarian, tubal, and primary peritoneal cancer (OC). The aim was to evaluate short-term morbidity of cytoreductive surgery (CRS) and carboplatin HIPEC.


METHODS
Prospective feasibility study performed from January 2016 to December 2017. Twenty-five patients with primary OC (FIGO III-IV) received upfront or interval CRS combined with carboplatin HIPEC at dose 800 mg/m 2 . Primary outcome measurements: grade 3 to 5 adverse events within 30 days according to Common Terminology Criteria for Adverse Events. Secondary outcome measurements: reoperation rate, length of hospital stay, readmission rate, and time from surgery to systemic chemotherapy administration.


RESULTS
No deaths (grade 5) or grade 4 adverse events were observed. Eleven patients (44.0%) experienced at least one grade 3 adverse event, the most common being an infection (28.0%) and neutropenia (12.0%). The reoperation rate was 8.0%. The median hospital stay was 14 days (range 9-25 days), and five patients (25.0%) were readmitted within 30 days after surgery. Median time from surgery to the administration of the first dose of systemic chemotherapy was 41 days (range 24-81 days).


CONCLUSION
Our small-scale prospective study supports that CRS and carboplatin HIPEC used for primary advanced-stage OC is feasible with acceptable morbidity.
['Mikkelsen|Mette Schou|MS|http://orcid.org/0000-0001-5943-7037', 'Christiansen|Thora|T|', 'Petersen|Lone Kjeld|LK|', 'Blaakaer|Jan|J|', 'Iversen|Lene Hjerrild|LH|']
D000328:Adult D000368:Aged D000971:Antineoplastic Combined Chemotherapy Protocols D016190:Carboplatin D000077216:Carcinoma, Ovarian Epithelial D017024:Chemotherapy, Adjuvant D065426:Cytoreduction Surgical Procedures D005185:Fallopian Tube Neoplasms D005260:Female D006801:Humans D006979:Hyperthermia, Induced D008875:Middle Aged D020360:Neoadjuvant Therapy D010051:Ovarian Neoplasms D017239:Paclitaxel D010534:Peritoneal Neoplasms D011446:Prospective Studies
cytoreductive surgery hyperthermic intraperitoneal chemotherapy complications ovarian cancer